Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Tennessee: - Memorial Hospital — Chattanooga, Tennessee
- Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
- Pulmonary Medicine Center of Chattanooga-Hixson — Hixson, Tennessee
- Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
- Baptist Memorial Hospital for Women — Memphis, Tennessee
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Tennessee: - East Tennessee Childrens Hospital — Knoxville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Tennessee: - Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Tennessee: - Saint Jude Children's Research Hospital — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Tennessee: - Sarah Canon Research Institute (SCRI) Oncology Partners — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 2 Recruiting Academic/Other
This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called ki…
Sponsor: University of California, San Francisco
NCT ID: NCT07110246
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Industry
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of…
Sponsor: Neonc Technologies, Inc.
NCT ID: NCT06047379
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Tennessee: - Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Tennessee: - SCRI Oncology Partners — Nashville, Tennessee
- Vanderbilt Ingram Cancer Center — Nashville, Tennessee
Phase 1 Recruiting Industry
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent adva…
Sponsor: Nested Therapeutics, Inc
NCT ID: NCT06326411
Sites in Tennessee: - SCRI Oncology Partners — Nashville, Tennessee
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
Phase 1 Recruiting Industry
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after stand…
Sponsor: RasCal Therapeutics, Inc.
NCT ID: NCT04678648
Sites in Tennessee: - Sarah Cannon, SCRI Oncology Partners — Nashville, Tennessee
Phase 1 Recruiting Industry
This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful. The purpose of thi…
Sponsor: Boehringer Ingelheim
NCT ID: NCT05916313
Sites in Tennessee: - SCRI Oncology Partners — Nashville, Tennessee
EARLY Phase 1 Recruiting Academic/Other
This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.
Sponsor: Eben Rosenthal
NCT ID: NCT07493447
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
EARLY Phase 1 Recruiting Academic/Other
This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.
Sponsor: Vanderbilt-Ingram Cancer Center
NCT ID: NCT05996432
Sites in Tennessee: - Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
EARLY Phase 1 Recruiting Academic/Other
High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patien…
Sponsor: Eben Rosenthal
NCT ID: NCT07210632
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Recruiting Industry
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT04427384
Sites in Tennessee: - CHI Memorial Hospital, CommonSpirit — Chattanooga, Tennessee
Recruiting Academic/Other
The study is being done to learn more about the long-term health and well-being of participants treated for medulloblastoma. The study is to decide which evaluations focusing on therapy-related lasting effects (or toxicities) should be con…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT07085325
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
NA Recruiting Academic/Other
The objective of this study is to estimate the feasibility and acceptability of cognitive training in the virtual reality setting with children undergoing radiotherapy for brain tumors. To achieve this goal, the investigators plan to study…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05947045
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee